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The central nervous system (CNS) plays an important
role in the regulation of appetite, energy expenditure,
and body weight. Understanding the neural pathways
involved is essential to the development of mechanism-
based approaches to the prevention and treatment of
obesity and diabetes (Fig. 1). Recent advances in MRI of
fast acquisition sequences and image-processing soft-
ware now enable us to noninvasively examine patterns
of brain neuronal activation in vivo using functional
MRI (fMRI). Using this technique, several studies have
demonstrated the complex interplay of activation in cor-
tical and subcortical regions that control the affective/
emotional responses to food that modulate feeding/
eating behavior (1,2). These responses may have an im-
portant role in driving and sustaining energy intake over
and above pure requirement, contributing to the obesity
epidemic.
An example of this approach is the elegant work of van
Bloemendaal et al. (3), which appears in this issue. The
authors examined the effects of GLP-1 agonists on regional
brain responses to food cues (images of food) using fMRI.
Their aim was to test the hypothesis that the behavioral
response (i.e., a reduction in food intake) following GLP-1
receptor activation is mediated through changes in appetite-
and reward-related brain areas. In a crossover, random-
ized, placebo-controlled trial of 48 subjects (16 obese
patients with type 2 diabetes [T2DM], 16 normoglycemic
obese, and 16 lean control subjects), they used fMRI to
determine the acute effects of intravenous administra-
tion of the GLP-1 receptor agonist exenatide, with or with-
out prior GLP-1 receptor blockade (exendin 9-39), on brain
responses to food pictures during a somatostatin pancreatic-
pituitary clamp. They observed increased brain responses
to food pictures in appetite- and reward-related brain
regions (insula and amygdala) in obese subjects (with
and without T2DM) versus lean subjects studied in the
fasted state. Acute administration of exenatide in T2DM
and normoglycemic obese subjects diminished the food-
related brain responses, which was associated with decreased
food intake. These effects were largely blocked by prior
GLP-1 receptor blockade using exendin 9-39 and were
independent of circulating metabolic and hormonal fac-
tors (e.g., glucose). These novel ﬁndings provide valuable
insights into the effects of GLP-1 analog therapy on neu-
ral pathways that could in part explain the effects of this
class of drugs on appetite suppression and resultant
weight loss.
The results from this interesting study clearly speak
for themselves. Nevertheless, the ﬁndings merit further
reﬂection. In clinical practice, treatment effects and re-
sponses to GLP-1 receptor agonists are not necessarily
constant at different stages of the treatment pathway (i.e.,
the response tends to be greater earlier in the treatment
pathway, at a less advanced stage of disease). Subjects with
T2DM included in this study would appear to be at
a relatively early stage of disease with comparatively
short duration of diabetes (median 7.0 [interquartile
range 4.2–10.7] years) and reasonable glycemic control
(HbA1c 51.6 6 2.4 mmol/mol) on either one or two oral hy-
poglycemic agents. Further studies investigating the effects of
GLP-1 agonists on CNS food-related responses in responders
versus nonresponders may offer insights about which
patients are more or less likely to respond to treatment
and whether there is a relationship with duration of disease.
Interestingly, as noted by van Bloemendaal et al., the
inhibitor exendin 9-39 used in this study has low uptake
in the brain, suggesting that the central effects of GLP-1
analogs are possibly mediated by its action on peripheral
receptors. This is relevant with the arrival of long-acting
GLP-1 receptor agonist molecules that are larger and
have lower CNS permeability. Understanding the connec-
tion between appetite, weight gain, and reward from food
is essential to developing effective weight maintenance
strategies. The knowledge that fMRI responses in reward-
related brain areas to food images are signiﬁcantly different
between lean and obese people also raises a question:
Does reward generate obesity, or is it a consequence of
obesity?
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Finally, this well-designed study by van Bloemendaal
et al. (3) is a good example of the integration of recent advances
in MRI with careful physiological studies in well-phenotyped
subgroups of individuals to address clinically relevant
questions. This study adds to a growing body of work
where fMRI has been used to study the brain response
to physiological stimuli such as fasting/refeeding (4); to
speciﬁc hormones such as leptin (5), ghrelin (6), peptide
tyrosine tyrosine (7), and GLP-1 (8); to therapeutic inter-
ventions such as caloric restriction (9), weight loss mainte-
nance (10), sibutramine (11), and Roux-en-Y bypass surgery
(12,13); and to the effects of common (14) and rare obesity-
associated genetic variants (15,16).
Such studies can drive the selection and validation
(and indeed rejection) of potential drug targets (17),
thereby increasing the probability of success of drug de-
velopment programs. At present, most imaging methods
do not meet biomarker status. However, if the techniques
used in the study by van Bloemendaal et al. (3) are dem-
onstrated to be robust and reproducible, then they could
be applied in future proof of concept studies for the clin-
ical evaluation of new drug candidates for the manage-
ment of obesity and T2DM.
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Figure 1—Neurohormonal regulation of appetite and reward (mod-
iﬁed from http://gut-brain-axis.org/). PYY, peptide tyrosine tyrosine.
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